ASCL1 and small cell lung carcinoma: Our network further highlights that the inhibition of Ascl1—a NE and SCLC-A & -A2 subtype marker downstream of the Notch2 receptor—and the activation of Myc facilitates the upregulation of mesenchymal markers.